FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription
- PMID: 18358809
- PMCID: PMC2323438
- DOI: 10.1016/j.cell.2008.01.018
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription
Abstract
Complex organisms require tissue-specific transcriptional programs, yet little is known about how these are established. The transcription factor FoxA1 is thought to contribute to gene regulation through its ability to act as a pioneer factor binding to nucleosomal DNA. Through genome-wide positional analyses, we demonstrate that FoxA1 cell type-specific functions rely primarily on differential recruitment to chromatin predominantly at distant enhancers rather than proximal promoters. This differential recruitment leads to cell type-specific changes in chromatin structure and functional collaboration with lineage-specific transcription factors. Despite the ability of FoxA1 to bind nucleosomes, its differential binding to chromatin sites is dependent on the distribution of histone H3 lysine 4 dimethylation. Together, our results suggest that methylation of histone H3 lysine 4 is part of the epigenetic signature that defines lineage-specific FoxA1 recruitment sites in chromatin. FoxA1 translates this epigenetic signature into changes in chromatin structure thereby establishing lineage-specific transcriptional enhancers and programs.
Figures
Similar articles
-
Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers.Genome Res. 2011 Apr;21(4):555-65. doi: 10.1101/gr.111534.110. Epub 2011 Jan 13. Genome Res. 2011. PMID: 21233399 Free PMC article.
-
Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression.Nucleic Acids Res. 2014 Feb;42(4):2245-56. doi: 10.1093/nar/gkt1236. Epub 2013 Nov 27. Nucleic Acids Res. 2014. PMID: 24288367 Free PMC article.
-
FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function.Nucleic Acids Res. 2016 Sep 30;44(17):8153-64. doi: 10.1093/nar/gkw498. Epub 2016 Jun 1. Nucleic Acids Res. 2016. PMID: 27257062 Free PMC article.
-
Pioneer of prostate cancer: past, present and the future of FOXA1.Protein Cell. 2021 Jan;12(1):29-38. doi: 10.1007/s13238-020-00786-8. Epub 2020 Sep 18. Protein Cell. 2021. PMID: 32946061 Free PMC article. Review.
-
Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling.Mol Cell Endocrinol. 2014 Jan 25;382(1):633-641. doi: 10.1016/j.mce.2013.04.026. Epub 2013 May 16. Mol Cell Endocrinol. 2014. PMID: 23684889 Review.
Cited by
-
KDM4B is a master regulator of the estrogen receptor signalling cascade.Nucleic Acids Res. 2013 Aug;41(14):6892-904. doi: 10.1093/nar/gkt469. Epub 2013 May 30. Nucleic Acids Res. 2013. PMID: 23723241 Free PMC article.
-
Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.Horm Cancer. 2013 Apr;4(2):61-9. doi: 10.1007/s12672-013-0131-4. Epub 2013 Jan 10. Horm Cancer. 2013. PMID: 23307762 Free PMC article. Review.
-
ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters.Nat Commun. 2015 Feb 3;2:6186. doi: 10.1038/ncomms7186. Nat Commun. 2015. PMID: 25645053 Free PMC article.
-
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.BMC Genomics. 2012 Jul 31;13:355. doi: 10.1186/1471-2164-13-355. BMC Genomics. 2012. PMID: 22849360 Free PMC article.
-
Genome-wide roles of Foxa2 in directing liver specification.J Mol Cell Biol. 2012 Dec;4(6):420-2. doi: 10.1093/jmcb/mjs037. Epub 2012 Jun 28. J Mol Cell Biol. 2012. PMID: 22750789 Free PMC article. No abstract available.
References
-
- Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merkenschlager M, et al. Chromatin signatures of pluripotent cell lines. Nature cell biology. 2006;8:532–538. - PubMed
-
- Badve S, T D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. FOXA1 expression in breast cancer - Correlation with luminal subtype A and survival. Clinical cancer research. 2007;13:4415–4421. - PubMed
-
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823–837. - PubMed
-
- Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, McMahon S, Karlsson EK, Kulbokas EJ, 3rd, Gingeras TR, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005;120:169–181. - PubMed
-
- Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–681. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA8011105/CA/NCI NIH HHS/United States
- R01 DK074967/DK/NIDDK NIH HHS/United States
- P01 CA080111-090002/CA/NCI NIH HHS/United States
- R01 DK074967-01A1/DK/NIDDK NIH HHS/United States
- R56 DK074967-01/DK/NIDDK NIH HHS/United States
- P50 CA089393/CA/NCI NIH HHS/United States
- R01 HG004069-02/HG/NHGRI NIH HHS/United States
- R56 DK074967/DK/NIDDK NIH HHS/United States
- P50 CA089393-060012/CA/NCI NIH HHS/United States
- P50 CA089393-070012/CA/NCI NIH HHS/United States
- 1R01 HG004069-02/HG/NHGRI NIH HHS/United States
- P01 CA080111-010002/CA/NCI NIH HHS/United States
- R01 HG004069/HG/NHGRI NIH HHS/United States
- P50 CA089393-080012/CA/NCI NIH HHS/United States
- P01 CA080111/CA/NCI NIH HHS/United States
- P01 CA080111-070002/CA/NCI NIH HHS/United States
- P01 CA080111-100002/CA/NCI NIH HHS/United States
- P01 CA080111-080002/CA/NCI NIH HHS/United States
- P01 CA080111-060002/CA/NCI NIH HHS/United States
- R01DK074967/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
